1. Home
  2. TRAK vs CRDL Comparison

TRAK vs CRDL Comparison

Compare TRAK & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAK

ReposiTrak Inc.

HOLD

Current Price

$10.44

Market Cap

186.2M

Sector

Technology

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

154.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRAK
CRDL
Founded
1990
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.2M
154.1M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
TRAK
CRDL
Price
$10.44
$1.23
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
101.7K
367.9K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
0.90%
N/A
EPS Growth
20.69
N/A
EPS
0.28
N/A
Revenue
$21,007,076.00
N/A
Revenue This Year
$6.61
N/A
Revenue Next Year
$10.04
N/A
P/E Ratio
$36.82
N/A
Revenue Growth
4.84
N/A
52 Week Low
$6.94
$0.88
52 Week High
$22.17
$1.71

Technical Indicators

Market Signals
Indicator
TRAK
CRDL
Relative Strength Index (RSI) 62.93 38.48
Support Level $10.03 $0.94
Resistance Level $10.64 $1.38
Average True Range (ATR) 0.46 0.06
MACD 0.02 -0.01
Stochastic Oscillator 83.33 5.26

Price Performance

Historical Comparison
TRAK
CRDL

About TRAK ReposiTrak Inc.

ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: